BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study Forty-two patients with advanced thymoma or thymic ...

The effect of transcatheter arterial chemoembolization on hepatitis C virus (HCV) kinetics in patients with HCV-associated hepatocellular carcinoma. This is an ASCO Meeting Abstract from the 2011 ASCO ...

May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...

Mycapssa (octreotide) is a brand-name drug that’s prescribed for certain adults with acromegaly. Mycapssa comes as a delayed-release oral capsule that’s typically taken twice per day. Octreotide is ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced the launch of the first and only generic version of Sandostatin LAR Depot, in the United States.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) on Tuesday the launch of the first and only generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S.